论文部分内容阅读
目的:探讨胺碘酮联合缬沙坦、氟伐他汀预防阵发性房颤复发的临床疗效。方法:随机选取阵发性房颤复律后患者85例,分为观察组43例和对照组42例。观察组口服胺碘酮加缬沙坦、氟伐他汀,对照组口服胺碘酮,观察12个月。结果:观察组房颤复发率明显下降并低于对照组有统计学差异(P<0.05)。观察组左房结构功能改善优于对照组,差异有统计学意义(P<0.05),观察组CRP水平在12个月后显著低于对照组(P<0.01)。结论:胺碘酮联合缬沙坦、氟伐他汀能更有效预防房颤复发。
Objective: To investigate the clinical efficacy of amiodarone combined with valsartan and fluvastatin in preventing the recurrence of paroxysmal atrial fibrillation. Methods: A random sample of 85 patients with paroxysmal atrial fibrillation after cardioversion was divided into observation group (43 cases) and control group (42 cases). The observation group was given oral amiodarone plus valsartan and fluvastatin, and the control group was given amiodarone orally for 12 months. Results: The recurrence rate of atrial fibrillation in observation group was significantly lower than that in control group (P <0.05). The improvement of left atrial function in observation group was better than that in control group (P <0.05). CRP level in observation group was significantly lower than that in control group after 12 months (P <0.01). Conclusion: Amiodarone combined with valsartan and fluvastatin can prevent recurrence of atrial fibrillation more effectively.